Frontlight ResearchEarly access
Taking people in NetherlandsPhase 3
Testing ambroxol in people with Gaucher disease type 3
Tests whether ambroxol changes a spinal fluid marker in Gaucher disease type 3.
Key facts
- Who runs it
- Amsterdam UMC Stichting
- Where
- Amsterdam, NetherlandsSee the site
- Trial code
- EU 2024-514012-28-00
- EudraCT 2021-002550-82
- NL-OMON51936
- Registry title
- Effectiveness of ambroxol in children and adults with Gaucher disease 3: n-of-1 series
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 4 people, planned
- Started
- 25 Nov 2024
- Expected to end
- 1 Sept 2027
- Type of study
- Interventional
- Record updated
- 25 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and adults with Gaucher disease type 3 who already receive enzyme replacement therapy. It looks at how ambroxol changes a marker in spinal fluid.
- Age
- All ages, up to 64 Years
- Sex
- All sexes can join.
- Disease stage
- Gaucher disease type 3, with documented low GCase enzyme activity and a GBA gene type that fits type 3.
- Earlier treatment
- Must be on enzyme replacement therapy (ERT), with the treatment ongoing at enrollment. Must not have received an investigational product within 30 days before enrollment.
- Biomarker or test result
- Documented deficiency of GCase activity and a GBA genotype fitting Gaucher disease type 3.
Main reasons for not taking part
- Depends on blood transfusions
- Known allergy or bad reaction to ambroxol or its inactive ingredients
- Pregnant or breastfeeding
- Cannot swallow powder and has no other way to take it, such as a gastrostomy
- Cannot or will not follow the study requirements
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- The patient or the parent(s) / legal guardian(s) must provide written informed consent before start of the study
- Male and female patients with documented deficiency of GCase activity and GBA genotype fitting GD3
- Male and female patients of all ages
- Able to travel to the study site
- Patients receive ERT with treatment ongoing at the time of enrollment
Who cannot take part
- The patient has received an investigational product within 30 days prior to enrollment
- Known hypersensitivity reactions, intolerance or adverse reactions to ambroxol or to the inactive ingredients
- Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients
- The patient is transfusion dependent
- Pregnancy, because there are no sufficient data for the use of ambroxol in pregnant women (see Summary of Product Characteristics (SPC))
- The patient is lactating. Ambroxol crosses into the breast milk. As there is no adequate experience in humans to date, ambroxol should not be used in lactation in a study setting (see SPC)
- The patient is unwilling or, in the investigator's opinion, unable to adhere to the requirements of the study
- The patient is unable to swallow powder and has no other enteral access (e.g. gastrostomy)
Where in Netherlands
- Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people
About the trial
What the trial wants to find out
Effect of ambroxol on cerebrospinal fluid (CSF) Lyso-GL1 in GD3 patients receiving ambroxol.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Effectiveness of ambroxol in children and adults with Gaucher disease 3: n-of-1 series
- Plain-language title
- Testing ambroxol in people with Gaucher disease type 3Generated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 25 November 2024